{"entity":{"id":"sstr5","kind":"target","name":"SSTR5","aka":["somatostatin receptor 5","Somatostatin receptor type 5"],"tldr":"SSTR5 (Somatostatin receptor type 5) is a gene. The public catalogues list it as a drug target and a biomarker, and an approved or late-stage drug is recorded against it. Tied to Neuroendocrine tumours.","summary":"Receptor for somatostatin 28 and to a lesser extent for somatostatin-14. The activity of this receptor is mediated by G proteins which inhibit adenylyl cyclase. Increases cell growth inhibition activity of SSTR2 following heterodimerisation.\n\nCIViC holds 1 clinical evidence item and 0 assertions across 2 variants, naming Pasireotide. Open Targets scores its association with cancer at 0.58 (direct and indirect evidence; datatypes literature 0.81, genetic association 0.00, clinical 0.91). In OnCo, 1 product record names it (Pasireotide).","asOf":"2026-09-23","links":[{"label":"HGNC HGNC:11334","url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:11334"},{"label":"UniProt P35346","url":"https://www.uniprot.org/uniprotkb/P35346/entry"},{"label":"NCBI Gene 6755","url":"https://www.ncbi.nlm.nih.gov/gene/6755"},{"label":"Ensembl ENSG00000162009","url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000162009"}],"tags":["cancer-genes-wave"],"related":["civic","open-targets"],"cancers":["neuroendocrine"],"sections":[],"technologies":[],"targets":[],"drugs":["pasireotide"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: Open Targets known-drug datatype score 0.97; CIViC holds 1 clinical evidence items on its variants. Evidence tier \"approved-drug\" is the strongest of those signals.","Prevalence not recorded: none of the sources gives a positivity rate."],"provenance":{"editedBy":"scripts/fetch-cancer-genes.ts (CIViC, Open Targets, IntOGen, HGNC, UniProt)","editedOn":"2026-09-23"},"symbol":"SSTR5","role":["drug-target","biomarker"],"evidenceTier":"approved-drug","sources":[{"label":"HGNC HGNC:11334","url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:11334","note":"approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)"},{"label":"UniProt P35346","url":"https://www.uniprot.org/uniprotkb/P35346/entry","note":"protein name, function text, keywords and locations (REST API)"},{"label":"CIViC gene SSTR5","url":"https://civicdb.org/features/5499","note":"1 evidence items, 0 assertions, 2 variants; diseases: Neuroendocrine Tumour (GraphQL API, CC0)"},{"label":"Open Targets ENSG00000162009","url":"https://platform.opentargets.org/target/ENSG00000162009/associations","note":"association with cancer (MONDO_0004992) 0.58; per-cancer scores at or above 0.5: neuroendocrine neoplasm 0.60 (GraphQL API, CC0)"}],"specificity":"tumour-associated","distribution":"one-type","specificityNote":"Tumour-associated overexpression: HPA finds the RNA tissue enhanced in normal adrenal gland, blood vessel, heart muscle, kidney, so the tumour and the normal tissue it comes from share the target and the medicine relies on the difference in level. HPA SSTR5: RNA tissue enhanced (adrenal gland 2 nTPM, blood vessel 3 nTPM, heart muscle 2 nTPM); no normal tissue stained high. Distribution: 1 cancer family in the corpus carries a prevalence row, label threshold or catalogue link for it (Neuroendocrine tumours); approvals of single-target medicines aimed at it also list Brain and spinal cord tumours (all types), not counted; Open Targets associates it with 1 specific cancer type at or above 0.5 (carcinoid tumor). (Rule 7 of scripts/fetch-target-specificity.ts.)","specificitySources":[{"label":"Human Protein Atlas SSTR5 tissue","url":"https://www.proteinatlas.org/ENSG00000162009-SSTR5/tissue","note":"RNA tissue and blood lineage specificity, normal tissue antibody staining (version 25.1, CC BY-SA 3.0)"},{"label":"Human Protein Atlas SSTR5 pathology","url":"https://www.proteinatlas.org/ENSG00000162009-SSTR5/pathology","note":"patients per staining level per cancer type (version 25.1, CC BY-SA 3.0)"},{"label":"Open Targets ENSG00000162009 associations","url":"https://platform.opentargets.org/target/ENSG00000162009/associations","note":"cancer associations at or above 0.5 (CC0)"}],"hgnc":"HGNC:11334","ensembl":"ENSG00000162009","uniprot":"P35346","entrez":"6755","firstDescribed":1993,"firstDescribedBasis":"sequence","firstDescribedNote":"Earliest sequence paper UniProt cites for the protein: Yamada et al, Biochem. Biophys. Res. Commun, 1993, \"Cloning, functional expression and pharmacological characterization of a fourth (hSSTR4) and a fifth (hSSTR5) human somatostatin receptor subtype\".","firstDescribedSource":"https://pubmed.ncbi.nlm.nih.gov/8373420/","biology":"Receptor for somatostatin 28 and to a lesser extent for somatostatin-14. The activity of this receptor is mediated by G proteins which inhibit adenylyl cyclase. Increases cell growth inhibition activity of SSTR2 following heterodimerisation. Location: Cell membrane (UniProt). Locus 16p13.3 (HGNC).","whereFound":["Neuroendocrine tumours: Open Targets association 0.60 with neuroendocrine neoplasm (MONDO_0019496); CIViC evidence names this disease"],"targetClass":"other","prevalence":[]},"route":"/targets/sstr5/","neighbours":{"collection":[{"id":"civic","kind":"collection","name":"CIViC","route":"/collections/civic/"},{"id":"open-targets","kind":"collection","name":"Open Targets Platform","route":"/collections/open-targets/"}],"cancer":[{"id":"neuroendocrine","kind":"cancer","name":"Neuroendocrine tumours","route":"/cancers/neuroendocrine/"}],"drug":[{"id":"pasireotide","kind":"drug","name":"Pasireotide","route":"/drugs/pasireotide/"}]}}